Who
Roger M. Perlmutter
Director and Officer
Company insider
Files Form 4 as: Director and Officer, Eikon Therapeutics; Director, Ngm Biopharmaceuticals; Exe V-P & Pres, MRL, Merck & Company; Director, Microbot Medical; EVP, Research & Development, Amgen.
In numbers
- Trades disclosed
- 77
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $26.5M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 3 Apr 2006
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —268,176 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —268,176 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EIKN Eikon TherapeuticsBiotechnology | SEC FORM 4 Code C | —284,857 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,268,891 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —855,512 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,268,891 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —855,512 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EIKN Eikon TherapeuticsBiotechnology | SEC FORM 4 Code C | —284,857 | filing |
| 5 Apr 2024filed 8 Apr 2024 | Ngm Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —78,407 | filing |
| 5 Apr 2024filed 8 Apr 2024 | Ngm Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —24,222 | filing |
| 5 Apr 2024filed 8 Apr 2024 | Ngm Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —46,238 | filing |
| 10 May 2023filed 12 May 2023 | Ngm Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —78,407 at $0.00 | filing |
| 18 May 2022filed 20 May 2022 | Ngm Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —24,222 at $0.00 | filing |
| 8 Jun 2021filed 10 Jun 2021 | Ngm Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —46,238 at $0.00 | filing |
| 1 May 2020filed 5 May 2020 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —151,029 at $0.00 | filing |
| 28 Feb 2020filed 3 Mar 2020 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code A | $2.7M35,049 at $76.56 | filing |
| 3 May 2019filed 7 May 2019 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —141,134 at $0.00 | filing |
| 25 Feb 2019filed 27 Feb 2019 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code A | $2.6M32,937 at $80.38 | filing |
| 8 Nov 2018filed 8 Nov 2018 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —225,443 at $0.00 | filing |
| 8 Nov 2018filed 8 Nov 2018 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $10.1M225,443 at $44.98 | filing |
News
Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?AMGN · insidermonkey.com · 21 Oct 2026Merck's KEYTRUDA Plus Padcev Wins EU Approval For Muscle-Invasive Bladder CancerMRK · rttnews.com · 21 Oct 2026Contrasting Merck & Co., Inc. (NYSE:MRK) and ABVC BioPharma (NASDAQ:ABVC)MRK · themarketsdaily.com · 21 Oct 2026Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AMGN · fool.com · 20 Oct 2026AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026AMGN · prnewswire.com · 20 Oct 2026Merck (MRK) Has New Cancer Treatments. Can They Outgrow the Keytruda Patent Cliff?MRK · insidermonkey.com · 20 Oct 2026
0 headlines in the last 90 days name Roger M. Perlmutter; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.